Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

EYEG vs CBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CBIO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)

CBIO Overall Winner 6-Pillar Tally: EYEG 1 – 4 CBIO (1 Tie) Matrix Metrics: EYEG 2 – 6 CBIO

As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over EYEG (EYEG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EYEG carries a Unified Composite Score of 55.0/100 (HOLD) at $33.73 (N/M Forward P/E, N/A operating margin), whereas CBIO carries 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin).

  • Composite vs. Pillar Nuance: While EYEG currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. CBIO 49.2/100 HOLD), CBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EYEG vs CBIO
EYEG US Equity
EYEG
Institutional Equity
$33.73
+0.48% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.13β · 5% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 73.0 Fund 61.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.7 · SMA20: $33.74 · SMA50: $33.69
CBIO NASDAQ Head-to-Head Winner
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap $539.5M
TTM Revenue $15M
Forward P/E N/M
Beta / 30D Vol 1.18β · 60% Vol
Unified Composite Score
49.2 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.1 · SMA20: $13.45 · SMA50: $14.10

6-Pillar Scorecard Institutional Category Breakdown (EYEG 1 – 4 CBIO)

Columns: Metric · EYEG · CBIO
1. Valuation Multiples CBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 16.8x
2. Growth & Scale CBIO
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $15M
Market Cap N/A $539.5M
3. Profitability & Quality CBIO
Gross Margin N/A 100.0%
Operating Margin N/A -1228.4%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -160.8%
4. Balance Sheet & Cash Flow CBIO
Cash Generation (TTM) N/A -$162M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $287M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EYEG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 215.9% (98th %ile)
Put/Call OI Skew N/A 1.00x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EYEG (2) vs CBIO (6)
Institutional Metric EYEG CBIO Criterion Row Edge
Market Capitalization
Scale
N/A $539.5M Larger Scale CBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth CBIO
Operating Margin (TTM)
Profitability
N/A -1228.4% Higher Margin CBIO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin CBIO
Return on Equity (ROE)
Capital Efficiency
N/A -160.8% Higher ROE CBIO
52-Week Range Position
Momentum
15% ($33–$36) 23% ($9–$27) Stronger Trend CBIO
Beta / 30D Volatility
Risk Regime
0.13β · 5% Vol 1.18β · 60% Vol Lower Realized Risk EYEG
Unified Institutional Score
Composite Signal
55.0 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite EYEG
Trailing 12M Revenue (USD)
Operating Scale
N/A $15M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 16.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$162M ($287M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EYEG +1.71 pp
EYEG: +0.42% · CBIO: -1.29%
3M Horizon EYEG +22.0 pp
EYEG: -2.2% · CBIO: -24.2%
6M Horizon EYEG +31.84 pp
EYEG: -3.9% · CBIO: -35.74%
1Y Horizon CBIO +5.64 pp
EYEG: -5.87% · CBIO: -0.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EYEG vs CBIO. Trailing 12-month operating profitability (EYEG N/A vs CBIO -1228.4%) and valuation multiples (EYEG N/M vs CBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EYEG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
CBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15M
Gross Margin100.0%
Op. Margin-1228.4%
ROE / Fwd P/E-160.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EYEG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact EYEG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 215.9%
IV Percentile 98th %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EYEG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $539.5M market capitalization and -1228.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EYEG vs CBIO Key Questions & Quantitative Answers

As of Nov 20, 2026, Crescent Biopharma, Inc. (CBIO) is the stronger overall head-to-head candidate over EYEG (EYEG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). EYEG carries a Unified Composite Score of 55.0/100 (HOLD) at $33.73 (N/M Forward P/E, N/A operating margin), whereas CBIO carries 49.2/100 (HOLD) at $13.00 (N/M Forward P/E, -1228.4% operating margin). Composite vs. Pillar Nuance: While EYEG currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. CBIO 49.2/100 HOLD), CBIO captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: EYEG trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.7); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CBIO leads the Growth & Scale pillar: EYEG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin). On trailing 12-month operating scale, EYEG generates N/A in USD-normalized revenue versus $15M for CBIO. In operating R&D and SG&A reinvestment, EYEG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBIO.

CBIO screens cheaper on headline valuation multiples. EYEG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EYEG (N/A ROE) versus CBIO (-160.8% ROE) capital efficiency.

In options market volatility and institutional positioning, EYEG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.13β · 5% Vol realized risk). By comparison, CBIO carries 215.9% implied volatility (98th %ile, Extreme (>80th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.18β · 60% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.